Clinical Trial Phases

As drug development becomes increasingly global, Phase 2 clinical trials are no longer limited to single-country designs. Sponsors are now conducting multi-regional and multi-ethnic Phase 2 studies to ensure broader representation, regulatory efficiency, and generalizability of results. However, designing such studies introduces new layers of complexity—including logistical, regulatory, cultural, and scientific challenges. This tutorial explores the key considerations for successfully planning and conducting international Phase 2 trials involving diverse populations.
Click to read the full article.

Conducting clinical trials in rare diseases presents unique challenges that are especially pronounced in Phase 2, where early efficacy and dose optimization must be demonstrated. With small, geographically dispersed patient populations and limited historical data, Phase 2 studies in rare diseases demand innovative approaches to design, feasibility, and regulatory strategy. This tutorial explores the critical elements of planning and executing effective Phase 2 trials in rare and orphan indications.
Click to read the full article.

Biologic therapies such as monoclonal antibodies, peptides, fusion proteins, and gene therapies have revolutionized treatment across oncology, autoimmune, and rare diseases. However, because they are derived from living organisms, biologics carry a unique risk: immunogenicity. This refers to the body’s immune response to the biologic agent, which can affect both safety and efficacy. In Phase 2 clinical trials, immunogenicity assessment becomes critical for guiding dose selection, understanding therapeutic durability, and informing Phase 3 designs. This tutorial explores the why, how, and when of conducting immunogenicity evaluations in Phase 2 biologic studies.
Click to read the full article.